UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.362

Sortiert nach

'Candidatus Mycoplasma haemominutum', a low-virulence epierythrocytic parasite of cats

International journal of systematic and evolutionary microbiology, 2001-05, Vol.51 (3), p.815-817

2001

Volltextzugriff (PDF)

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

Diabetes, obesity & metabolism, 2010-06, Vol.12 (6), p.485-494

2010

Volltextzugriff (PDF)

Alpha cell function in health and disease : influence of glucagon-like peptide-1

Diabetologia, 2005-09, Vol.48 (9), p.1700-1713

2005

Volltextzugriff (PDF)

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2005-08, Vol.90 (8), p.4888-4894

2005

Volltextzugriff (PDF)

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.775-783

2011

Volltextzugriff (PDF)

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Diabetologia, 2006-09, Vol.49 (9), p.2049-2057

2006

Volltextzugriff (PDF)

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

Diabetic medicine, 2008-04, Vol.25 (4), p.435-441

2008

Volltextzugriff (PDF)

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

Diabetes, obesity & metabolism, 2010-09, Vol.12 (9), p.780-789

2010

Volltextzugriff (PDF)

Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance

Diabetologia, 2000-12, Vol.43 (12), p.1498-1506

2000

Volltextzugriff (PDF)

Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

Diabetologia, 2013-08, Vol.56 (8), p.1752-1760

2013

Volltextzugriff (PDF)

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

Diabetes, obesity & metabolism, 2011-03, Vol.13 (3), p.193-203

2011

Volltextzugriff (PDF)

assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

Diabetes, obesity & metabolism, 2010-06, Vol.12 (6), p.495-509

2010

Volltextzugriff (PDF)

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

Diabetologia, 2011-08, Vol.54 (8), p.1985-1991

2011

Volltextzugriff (PDF)

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

Diabetes, obesity & metabolism, 2008-11, Vol.10 (11), p.1057-1061

2008

Volltextzugriff (PDF)

Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial

Diabetic medicine, 2014-10, Vol.31 (10), p.1178-1184

2014

Volltextzugriff (PDF)

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man

Diabetes, obesity & metabolism, 2013-01, Vol.15 (1), p.72-76

2013

Volltextzugriff (PDF)

Salmonella Oranienburg Isolated from Horses, Wild Turkeys and An Edible Home Garden Fertilized with Raw Horse Manure

Zoonoses and public health, 2014-02, Vol.61 (1), p.64-71

2014

Volltextzugriff (PDF)

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

Hormone and metabolic research, 2009-12, Vol.41 (12), p.905

2009

Volltextzugriff (PDF)

Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with Type 2 diabetes

Diabetic medicine, 2007-09, Vol.24 (9), p.955-961

2007

Volltextzugriff (PDF)

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

Diabetic medicine, 2007-09, Vol.24 (9), p.955

2007

Volltextzugriff (PDF)

Canine granulocytic anaplasmosis: A review

Journal of veterinary internal medicine, 2009-11, Vol.23 (6), p.1129-1141

2009

Volltextzugriff (PDF)

Characterization of Anaplasma phagocytophilum Major Surface Protein 5 and the Extent of Its Cross-Reactivity with A. marginale

Clinical and Vaccine Immunology, 2007-03, Vol.14 (3), p.262-268

2007

Volltextzugriff (PDF)

Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

Hormone and metabolic research, 2007-03, Vol.39 (3), p.218-223

2007

Volltextzugriff (PDF)

A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM

Diabetologia, 1995-10, Vol.38 (10), p.1213-1217

1995

Volltextzugriff (PDF)

Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus

Journal of feline medicine and surgery, 2004-04, Vol.6 (2), p.83-88

2004

Volltextzugriff (PDF)

1 – 25 von 3.362

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Nature - Connect here FIRST to enable access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.006)
Mit Volltextzugriff
(2.928)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(1.564)
MEDLINE
(1.482)
Ingenta
(1.211)
Journals@Ovid Full Text
(1.096)
NUS Single-Journal Subscriptions
(1.039)
Elsevier ScienceDirect Journals Collection
(606)
IngentaConnect Journals
(513)
Wiley Online Library
(477)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(450)
Wiley Online Library
(297)
Oxford University Press Journals Current
(277)
SpringerLink_现刊
(193)
American Physical Society Journals
(180)
PROLA (Physical Review Online Archive)
(167)
JSTOR Complete Journals
(164)
Oxford Journals 2020 Medicine
(158)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(132)
SAGE Journals
(86)
IEEE Xplore
(72)
Taylor & Francis Journals Auto-Holdings Collection
(70)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

'Candidatus Mycoplasma haemominutum', a low-virulence epierythrocytic parasite of cats

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

Alpha cell function in health and disease : influence of glucagon-like peptide-1

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance

Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man

Salmonella Oranienburg Isolated from Horses, Wild Turkeys and An Edible Home Garden Fertilized with Raw Horse Manure

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with Type 2 diabetes

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

Canine granulocytic anaplasmosis: A review

Characterization of Anaplasma phagocytophilum Major Surface Protein 5 and the Extent of Its Cross-Reactivity with A. marginale

Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM

Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus

Aktive Filter

Suchergebnisse filtern